| 7.44 -0.75 (-9.16%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.8 |
1-year : | 11.14 |
| Resists | First : | 8.39 |
Second : | 9.53 |
| Pivot price | 7.55  |
|||
| Supports | First : | 6.53 |
Second : | 5.44 |
| MAs | MA(5) : | 8 |
MA(20) : | 7.47 |
| MA(100) : | 5.93 |
MA(250) : | 3.89 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 64.8 |
D(3) : | 73.9 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 12.43 | Low : | 1.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IBRX ] has closed above bottom band by 43.3%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.29 - 8.33 | 8.33 - 8.37 |
| Low: | 7.3 - 7.35 | 7.35 - 7.39 |
| Close: | 7.35 - 7.43 | 7.43 - 7.5 |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Fri, 24 Apr 2026
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Fri, 24 Apr 2026
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - NewMediaWire
Fri, 24 Apr 2026
IBRX Stock Slides As FDA Warning Letter Sparks Class Actions - StocksToTrade
Fri, 24 Apr 2026
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Fri, 24 Apr 2026
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1,030 (M) |
| Shares Float | 378 (M) |
| Held by Insiders | 63.6 (%) |
| Held by Institutions | 16.9 (%) |
| Shares Short | 135,540 (K) |
| Shares Short P.Month | 132,440 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.5 |
| Profit Margin | 0 % |
| Operating Margin | -169 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 407 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -305 (M) |
| Levered Free Cash Flow | -213 (M) |
| PE Ratio | -19.58 |
| PEG Ratio | 0 |
| Price to Book value | -14.89 |
| Price to Sales | 67.64 |
| Price to Cash Flow | -25.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|